navitoclax + gemcitabine

Navitoclax + gemcitabine is a combination regimen of two small molecule antineoplastic agents: **navitoclax**, a potent oral inhibitor of anti-apoptotic Bcl-2 family proteins (also known as a BH3 mimetic), and **gemcitabine**, a nucleoside analog and DNA synthesis inhibitor. Navitoclax promotes apoptosis in cancer cells by binding and inhibiting Bcl-2, Bcl-xL, and Bcl-w, thus releasing pro-apoptotic factors and triggering cell death. Gemcitabine inhibits DNA synthesis by incorporating into DNA and preventing chain elongation, which also induces cellular senescence in some tumor models. In preclinical models, navitoclax and gemcitabine demonstrate synergy, with navitoclax acting as a senolytic to trigger apoptotic death in tumor cells rendered senescent by gemcitabine or combined treatments (such as radiation)[1][2][5]. Early-phase clinical studies show this combination is generally well tolerated, with dose-limiting toxicities including thrombocytopenia and elevated liver enzymes[1][2]. Primary development indication is for advanced solid tumors, including ongoing investigation for malignant meningioma[1][4][5].

Brand names

navitoclax + gemcitabine

Other names

navitoclax and gemcitabineABT-263 and gemcitabineABT263 and gemcitabineABT 263 and gemcitabine